Symptomatic drug therapy should be initiated when parkinsonian symptoms become bothersome to the patient. L-dopa remains the most powerful antiparkinsonian agent, but a minority of treated ...

The odds ratio for exposure to L-dopa in the IPD patients with PN was 12.4 (95% confidence interval, 1.4–109.1). There were no differences between the groups in the use of other PD drugs ...

The use of this drug is limited by the development of psychiatric ... More information: Carina Plewnia et al, Rewarding properties of L-Dopa in experimental parkinsonism are mediated by sensitized ...

We examined the effect of L-DOPA in the dose used for GH stimulation on the LH,FSH and Pr levels in 9 subjects with Turner syndrome, who had never received estrogens. We found the following (mean ...

NLX-101 (F15599) is under development for the treatment of Rett syndrome and depression. The drug candidate is administered by oral route. The drug candidate is a new chemical entity (NCE). The drug ...

Mavoglurant is under development for the treatment of cocaine use disorder, alcohol use disorder and for language learning in young children with fragile X syndrome (FXS). The drug candidate is ...

Previous studies in a rat model of Parkinson disease (PD) have shown that dyskinesia induced by L-DOPA—a treatment-limiting adverse effect of long-term administration—is caused by the release ...

The standard medication levodopa does not always work against tremors in Parkinson's disease, especially in stressful situations. Propranolol, however, does work during stress, providing insight into ...